Steven Quay, MD, PhD

Physician-Scientist, Inventor, Author, TEDx Speaker, and Serial Entrepreneur

[Atossa Therapeutics @atossainc]

Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment” https://t.co/o1si3p6XVE

[Atossa Therapeutics @atossainc]

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update https://t.co/SwwU15V4Tq

[Atossa Therapeutics @atossainc]

Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial https://t.co/5VMsykbEnI

[Atossa Therapeutics @atossainc]

Atossa to Present at the Sidoti Small-Cap Virtual Conference https://t.co/JgICxUn3eV

[Atossa Therapeutics @atossainc]

Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer https://t.co/UX0ki5Ks3I

[Atossa Therapeutics @atossainc]

Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen https://t.co/Iwq3mdOMgl

[Atossa Therapeutics @atossainc]

Atossa Therapeutics Issues Letter to Shareholders https://t.co/1pbExVDPDO

[Atossa Therapeutics @atossainc]

Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations https://t.co/kopt8K0VjO

[Atossa Therapeutics @atossainc]

Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update https://t.co/9PsawOIext

[Atossa Therapeutics @atossainc]

Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy https://t.co/Z3qncR9qe4

[Atossa Therapeutics @atossainc]

Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D. https://t.co/Le1BHK3qre

[Atossa Therapeutics @atossainc]

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer https://t.co/UD4j5LMiOs

[Atossa Therapeutics @atossainc]

Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference https://t.co/xghv7YPbH6

[Atossa Therapeutics @atossainc]

Registration Now Open for Tribe Public’s Webinar Event “The Important Role For Inhalation Therapy In Oncology” Featuring The Management Team From Atossa Therapeutics on August 25, 2022 https://t.co/xicMhZeokY

[Atossa Therapeutics @atossainc]

Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board https://t.co/flr5GcuDuu

[Atossa Therapeutics @atossainc]

Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update https://t.co/ynatEj7NP3

[Atossa Therapeutics @atossainc]

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer https://t.co/uT0YQ0LE1U

[Atossa Therapeutics @atossainc]

Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference https://t.co/qlXAjumjDE

[Atossa Therapeutics @atossainc]

Registration Now Open for Tribe Public’s Webinar Event “The Important Role For Inhalation Therapy In Oncology” Featuring The Management Team From Atossa Therapeutics on August 25, 2022 https://t.co/QxCjLulnzw

[Atossa Therapeutics @atossainc]

Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board https://t.co/jOjnxhMRsS